Radioimmunotherapy for lymphoma - analysis of clinical trials and treatment algorithms

Ibritumomab, an (90)Yttrium ((90)Y) labelled radioimmunoconjugate, is registered in Europe to treat follicular lymphomas. Its mode of action combines the selectivity of monoclonal antibodies with the efficiency of radiotherapy, making it a unique and useful therapeutic agent. This paper is for haema...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Nuclear medicine review. Central & Eastern Europe 2007, Vol.10 (2), p.110-115
Hauptverfasser:	Jurczak, Wojciech, Hubalewska-Dydejczyk, Alicja, Giza, Agnieszka, Sowa-Staszczak, Anna, Huszno, Bohdan, Skotnicki, Aleksander B
Format:	Artikel
Sprache:	eng
Schlagworte:	Algorithms Antibodies, Monoclonal - therapeutic use Clinical Trials as Topic - trends Decision Support Systems, Clinical Europe Humans Lymphoma - radiotherapy Radioimmunotherapy - trends Radiopharmaceuticals - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Ibritumomab, an (90)Yttrium ((90)Y) labelled radioimmunoconjugate, is registered in Europe to treat follicular lymphomas. Its mode of action combines the selectivity of monoclonal antibodies with the efficiency of radiotherapy, making it a unique and useful therapeutic agent. This paper is for haemato-oncologists with a decent practice in lymphoma therapy, who have not yet used ibritumomab themselves. It summarizes clinical trials with radioimmunotherapy, indicating clinical situations where it may be specifically useful.
ISSN:	1506-9680